Oil prices remain volatile due to stalled US-Iran talks and ongoing tensions around the Hormuz Strait, despite increasing crude exports from Saudi Arabia and UAE. The reopening of the Hormuz Strait could boost Gulf crude exports further, reducing reliance on other regions. Meanwhile, attacks on Gulf oil facilities and tight LNG supply keep natural gas prices high, with demand expected to stay low through 2023. Technical analysis shows neutral-to-bullish outlooks for oil and bullish for natural gas in the near term.
Natural gas and oil market conditions provide context for this update on stalled Iran talks and Gulf crude flows. For readers following energy stocks, here is Pluang's market snapshot as of Sep 28, 2026 13:21 WIB: Among 38 priced US energy-sector stocks, 21 rose and 15 fell. Notable movers include Valero Energy Corporation (VLO) at USD 391.71 with a 1-day change of +1.17%, Occidental Petroleum Corporation (OXY) at USD 57.50 with +1.13%, and Chevron Corp (CVX) at USD 206.67 with +1.09%. Typical hold times on Pluang range from 56 to 101 days for these stocks.
Pi Network has started testing Protocol 28 following the successful completion of Protocol 27, with the Mainnet upgrade scheduled for October 16. Node operators must update to Protocol 28 by October 13 to participate in the upgrade. Despite these tec...
First Hydrogen Corp. has successfully built its unmanned ground vehicle (UGV), achieving a key development milestone and securing exclusive worldwide rights to the related patented technology for the patent's remaining life, with a 1% royalty on sale...
Pump.fun (PUMP) token price fell 4.23% within one hour to $0.004957 on September 28, despite being up 12.10% over the past 24 hours. The drop occurred on Binance's PUMP/USDT market, triggering $110,000 in long position liquidations across Binance, By...
Coiled Therapeutics plans to report initial safety and pharmacokinetic data for its new AO-252 cancer drug formulation by the end of 2026 after dosing up to 30 patients. The new lipid-based softgel aims to improve drug absorption and consistency, wit...
Poolbeg Pharma has dosed eight patients in its TOPICAL trial testing POLB 001 to prevent cytokine release syndrome (CRS), a dangerous immune reaction caused by cancer immunotherapy. The trial targets multiple myeloma patients receiving teclistamab, a...
